PDF(Pubmed)
Abstract：
Prodromal Alzheimer\'s disease (AD) is a neurodegenerative condition typically progressing to dementia within 3 years. We describe a case of a mild cognitive impairment (MCI) patient with biomarker evidence for amyloidosis, tau, and neurodegeneration who had minimal changes in clinical phenotype during an 11-year period. AD biomarkers were obtained with cerebrospinal fluid analysis and amyloid PET imaging, both of which supported a biological diagnosis of AD. However, the patient\'s neuropsychological profile remained stable over 11 years except for mild memory-retrieval changes. This case provides evidence that MCI with supportive AD biomarkers may have an atypically minimal progression.
摘要：
前驱阿尔茨海默病（AD）是一种神经退行性疾病，通常在3年内发展为痴呆。我们描述了一例轻度认知障碍（MCI）患者的生物标志物证据为淀粉样变性，tau,以及在11年期间临床表型变化最小的神经变性。AD生物标志物通过脑脊液分析和淀粉样蛋白PET成像获得，两者都支持AD的生物学诊断。然而,除了轻度记忆恢复改变外,患者的神经心理学特征在11年中保持稳定.该病例提供了证据，表明具有支持性AD生物标志物的MCI可能具有非典型的最小进展。
